BAT1806 vs Levilimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline

BAT1806 · Tofidence

Marketed by Organon and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Partial signal

NCT03830203 · Phase 3 · completed

The study was randomized, quadruple-blind, and actively controlled with EU-licensed Actemra, enrolling 621 participants; its primary endpoint was the clinical ACR20 response at 6 months. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response (6 months): ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins (met)

Result source: NCT03830203

Levilimab · Ilsira

Marketed by Biocad

Phase 3 in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT04227366 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 154 patients that measured ACR20 response, a validated rheumatoid arthritis disease-activity measure, at week 12. Levilimab combined with methotrexate produced a much higher response rate than placebo combined with methotrexate (68.6% vs 38.5%).

Reported efficacy

ACR 20 response (Week 12); Low disease activity (Week 24): ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate). (met)

Result source: NCT04227366

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBAT1806Levilimab
ACR2069.9% vs 67.9%avs reference tocilizumabwk 24NCT0383020368.6% vs 38.5%a+30.1 vs placebowk 12NCT04227366
ACR50—Not posted · NCT03830203—Not posted · NCT04227366
ACR70—Not posted · NCT03830203—Not posted · NCT04227366
DAS28-CRP remission—Not posted · NCT03830203—Not posted · NCT04227366
HAQ-DI, change—Not posted · NCT03830203—Not posted · NCT04227366
Modified Sharp score, change—Not posted · NCT03830203—Not posted · NCT04227366

ACR20

BAT1806
69.9% vs 67.9%avs reference tocilizumabwk 24NCT03830203
Levilimab
68.6% vs 38.5%a+30.1 vs placebowk 12NCT04227366

ACR50

BAT1806
—Not posted · NCT03830203
Levilimab
—Not posted · NCT04227366

ACR70

BAT1806
—Not posted · NCT03830203
Levilimab
—Not posted · NCT04227366

DAS28-CRP remission

BAT1806
—Not posted · NCT03830203
Levilimab
—Not posted · NCT04227366

HAQ-DI, change

BAT1806
—Not posted · NCT03830203
Levilimab
—Not posted · NCT04227366

Modified Sharp score, change

BAT1806
—Not posted · NCT03830203
Levilimab
—Not posted · NCT04227366
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1806's landscape · Levilimab's landscape